These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 9825583)

  • 1. Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype.
    Marotta G; Bigazzi C; Bocchia M; Forconi F; Lauria F
    Haematologica; 1998 Sep; 83(9):853-4. PubMed ID: 9825583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical randomized comparative trial of ProMACE-CytaBOM regimen and CHOP regimen in treating non-Hodgkin's lymphoma].
    Hou M; Li L; Qiu M; Yan X; Zhu J; Gou HF
    Ai Zheng; 2005 Apr; 24(4):461-4. PubMed ID: 15820070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ProMACE-CytaBOM: combination chemotherapy for diffuse large cell lymphoma.
    Prokocimer M; Modan M; Rusoshansky S; Bairey O; Shaklai M
    Anticancer Res; 1989; 9(4):1233-5. PubMed ID: 2479327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [ProMACE-MOPP vs. ProMACE-CytaBOM polychemotherapies in the treatment of large-cell and unclassifiable non-Hodgkin's lymphomas].
    Pieresca C; Gobbi PG; Bertoloni D; Grignani G; Rossi A; Legnani MC; Giordano M
    Ann Ital Med Int; 1991; 6(3):267-72. PubMed ID: 1723289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
    Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
    Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
    Rigacci L; Carrai V; Nassi L; Alterini R; Longo G; Bernardi F; Bosi A
    Cancer; 2005 Mar; 103(5):970-7. PubMed ID: 15666323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group.
    Lorusso V; Palmieri G; Bianco AR; Abate G; Catalano G; De Vita F; Dammacco F; Lauta VM; Lucarelli G; Polimeno G; Mantovani G; D'Aprile M; Marzullo F; De Lena M
    Int J Oncol; 2000 Jan; 16(1):149-54. PubMed ID: 10601560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, predonisolone, bleomycin) therapy in elderly patients with aggressive non-Hodgkin lymphoma--a study of efficacy and safety, final report].
    Ishii K; Yamamoto Y; Shigeki T; Kitayama H; Hayashi K; Hirose A; Ohta T; Mugitani A; Fujino H; Yagi T; Hirai M; Teshima H; Katsurada T; Urase F; Kitajima H
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):39-44. PubMed ID: 15675580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma.
    Meyer RM; Quirt IC; Skillings JR; Cripps MC; Bramwell VH; Weinerman BH; Gospodarowicz MK; Burns BF; Sargeant AM; Shepherd LE
    N Engl J Med; 1993 Dec; 329(24):1770-6. PubMed ID: 7694148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
    Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
    Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Different chemotherapy protocols for intermediate and high grade malignant non-Hodgkin's lymphoma].
    Wang A; Luo Y; Wang Z
    Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):215-7. PubMed ID: 10920901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocyte colony stimulating factor (G-CSF) as adjunct therapy in relapsed-resistant high-grade non-Hodgkin's lymphoma.
    Zinzani PL; Martelli M; Tura S; Mandelli F
    Haematologica; 1993; 78(1):40-3. PubMed ID: 7684011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
    Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI
    J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VNCOP-B regimen in the treatment of high-grade non-Hodgkin's lymphoma in the elderly.
    Zinzani PL; Bendandi M; Gherlinzoni F; Mazza P; Salvucci M; Aitini E; Miggiano MC; Gozzetti A; Tura S
    Haematologica; 1993; 78(6):378-82. PubMed ID: 7513674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.
    Fisher RI; Longo DL; DeVita VT; Hubbard SM; Miller TP; Young RC
    Ann Oncol; 1991 Jan; 2 Suppl 1():33-5. PubMed ID: 1710487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter Phase II study of CyclOBEAP regimen for elderly patients with poor-prognosis aggressive lymphoma.
    Niitsu N; Okamoto M; Kohori M; Aoki S; Miura I; Hirano M
    Hematol Oncol; 2006 Dec; 24(4):220-6. PubMed ID: 16958147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The F-MACHOP regimen in the treatment of aggressive non-Hodgkin's lymphomas: a single center experience in 72 patients.
    Infanti L; Silvestri F; Fanin R; Salmaso F; Zaja F; Barillari G; Patriarca F; Geromin A; Cerno M; Damiani D; Baccarani M
    Haematologica; 1996; 81(6):521-8. PubMed ID: 9009439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.